Scientific Research Review SURPASS Clinical Trial Program (Type 2 Diabetes) The SURPASS program comprised phase III trials evaluating tirzepatide 5, 10, and 15 mg once weekly in patients with type 2 diabetes: SURPASS-1 (monotherapy, n=478): Tirzepatide reduced HbA1c by 1.87% (5 mg), 1.89% (10 mg), and 2.07% (15 mg) vs
The same rationale led to the designation of manual physical therapy as a Standard if appropriately trained clinicians are available
This is not straightforward
So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions
How Genetic Factors Influence Your Ideal Semaglutide Schedule Not everyone processes semaglutide at the same rate
Review medications: Some medications (certain antidepressants, antipsychotics, steroids) promote weight gain and may counteract semaglutide effects